|
Ankündigung des Beginns der Phase IIa - Studie von CK-2017357 "....Tuesday said it opened enrollment in a Phase IIa "Evidence of Effect" or EoE clinical trial of CK-2017357 in patients with generalized myasthenia gravis or MG. CK-2017357 is a fast skeletal muscle troponin activator and is the lead drug candidate that has emerged from the company's skeletal muscle contractility program. ..." http://www.rttnews.com/Content/QuickFacts.aspx?Id=1518786&SM… |
|
| aus der Diskussion: | ALS - Biotech machts möglich? |
| Autor (Datum des Eintrages): | Karl79 (05.01.11 14:39:10) |
| Beitrag: | 8 von 9 (ID:40803758) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |